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Results: LRC at 1 year was superior among patients in the experimental arm, treated with cetuximab maintenance (59% versus 47%). However, LRC was similar between both arms after 2 years of follow-up, as a result of increased locoregional recurrences after the first year in the maintenance group. Patients treated with adjuvant cetuximab do recover very soon from toxic effect after combined treatment.
Conclusions: Twelve weeks of cetuximab maintenance therapy after concomitant cetuximab + RT in locally advanced oropharyngeal carcinoma is feasible and improves clinical outcomes measured at 1 year. This improvement is not maintained after the second year suggesting that epidermal growth factor receptor blockade is not sufficient to completely eliminate the minimal residual disease. Key words: bioradiotherapy, cetuximab maintenance, oropharynx carcinoma introduction Treatment strategies for locally advanced squamous cell carcinoma of the head and neck (SCCHN) have been evolving in the last 20 years but without making substantial changes in the survival of these patients. Efforts have been made to improve locoregional control (LRC) and survival, and different therapeutic regimens including concurrent chemoradiotherapy (CRT), sequential CRT or bioradiation have been tested. Oropharyngeal cancer is the most common head and neck tumor in the European Union, with an incidence of 23 new cases per 100 000 inhabitants per year [1] .
To further improve the outcome of patients with locally advanced SCCHN, effective new treatments with less toxic effects are needed. Cetuximab is a chimeric monoclonal antibody that binds to the extracellular domain of epidermal growth factor receptor (EGFR) [2] , and in addition induces antibody-dependent cellular cytoxicity [3] . Several preclinical studies demonstrated that inhibition of EGFR by cetuximab increases the efficacy of radiotherapy (RT) [4, 5] . The combination of cetuximab plus RT has demonstrated superior efficacy when compared with RT alone in the phase III Bonner et al. trial [6] . The preclinical data support extending cetuximab after RT is completed [7, 8] .
Previous experiences have shown that tumor cells from the head and neck area get into accelerated repopulation phase, ∼30 days after RT initiation. In theory, this suggests that a schedule providing adequate radiation (two fractions per day) would be an advantageous treatment of these tumors during this rapid growing phase [9] . This accelerated fraction with concomitant boost (AFX-C) RT may reduce the volume of tissue treated at an accelerated rate, while reducing the overall treatment time and maintaining a similar total dose of standard RT [10] .
Cetuximab combined with accelerated concomitant boost RT is an option in the treatment of locally advanced head and neck cancers. Adding maintenance cetuximab to this treatment could play a role in hampering the viability of a possible residual disease. The objectives of the study were to evaluate the efficacy and safety of administering cetuximab after a curative intent treatment with RT and cetuximab in patients with locally advanced oropharynx cancers.
patients and methods study patients
From November 2005 to July 2007, previously untreated patients between 18 and 80 years old, with histologically proven, stage III-IV, non-metastatic, squamous cell carcinoma of the oropharynx were included in this trial. Patients have been followed-up until March 2011. Normal values for hematopoietic, hepatic and renal functions were required. Other inclusion criteria included Karnofsky performance score >60% and an adequate nutritional status at inclusion. Immunostaining of the tumor for EGFR was done in all specimens, although it was not required for eligibility. The protocol was approved by all ethics committees at the participating institutions, and all the patients provided written informed consent. Additional approval from ethics committees was also requested when it was decided to retrospectively analyze human papillomavirus (HPV) status, a new informed consent was required from patients still alive.
study design and treatment
This is a prospective, multicenter, randomized, open phase II pilot study. Patients were randomly assigned 1:1 to receive (group B, experimental group) or not (group A, control group) 12 weeks of adjuvant therapy with cetuximab (250 mg/m 2 weekly) after a treatment with AFX-C plus cetuximab at the standard dose (400 mg/m 2 as start dose 1 week before RT followed by 250 mg/m 2 weekly during RT). Stratification factors included Karnofsky performance status (70%-80% versus 90%-100%) and stage (III versus IV).
Patients in the arm A received a treatment protocol similar to the experimental arm of the Bonner et al. trial [6] , while those included in the arm B continued treatment with cetuximab at the dose of 250 mg/m 2 / weekly without any interruption after finalizing RT till completing 12 weeks of adjuvant treatment. RT consisted of AFX-C at 1.8 Gy/fraction/ day, 5 days/week to large field + 1.5 Gy/fraction/day to boost field for the last 13 treatment days to a total dose of 69.9 Gy/41 fractions/28 days.
Salvage neck dissection was performed in each case only with persistent nodal disease and primary tumor control after the first evaluation of response (from 12 weeks after the end of RT). When other surgery different from a salvage neck dissection at the end of definitive treatment was performed, it was considered as a locoregional failure.
study evaluations
In each arm, weekly evaluations were performed during treatment until minimum 12 weeks after the end of RT or until recovery from acute toxic effect to less than grade 2. Complete blood count and chemistry profile were performed every 3 weeks.
All patients were assessed for tumor response by laryngoscopy and radiographic methods (computed tomography or magnetic resonance imaging) 12 weeks after the end of RT. Physical evaluations were performed every 2 months during the first year, every 3 months during the second and third years and then every 6 months. Neck imaging assessments were performed every 6 months until the fifth year. Tumor responses were assessed following World Health Organization criteria [11] .
Translational research was performed on the paraffin-embedded tumor from the initial biopsy. Whenever sufficient tumor material was not available, results were expressed as 'not evaluated'. EGFR by immunohistochemistry was done routinely. HPV status in the tumor was analyzed using a high sensitive and specific short PCR ( protein chain reaction) fragment (SPF) [12] HPV DNA test and PCR/DNA ELISA immunoassay (DEIA) method as described by Kleter et al. [13] .
study end points
The primary end point of the study was LRC rate at 1 year in the experimental arm (arm B), using a control arm (arm A) to avoid a selection bias. LRC was defined as the complete disappearance of disease in the primary tumor and regional lymph nodes. The appearance of a second tumor within the radiation field was also regarded as a therapeutic failure. Secondary end points included LRC rates at 2 and 3 years, specific disease-free survival (SDFS), event-free survival (EFS), overall survival (OS) and the safety and toxic effect of concomitant accelerated RT plus cetuximab followed by 12 additional weeks of treatment with cetuximab. The acute toxic effect of the treatment was evaluated through the Common Terminology Criteria for Adverse Events of the National Cancer Institute, version 3.0. [14] . We also determined biologic molecular markers in the tumor to explore their possible prognostic significance.
statistical methods
At the time of study design, no data in the literature on the effectiveness of a complementary treatment with cetuximab after definitive RT in patients with SCCHN had been reported in the literature. Therefore, we designed an exploratory non-comparative phase II pilot study. We selected a homogeneous population of patients with oropharyngeal squamous cell carcinoma stage III-IV, who received additional treatment with 12 weeks of cetuximab after the completion of accelerated RT with a concomitant boost according to the study of Bonner et al. [6] . A control group perfectly comparable with the experimental group but without receiving adjuvant therapy was used to avoid a selection bias.
The main objective of the study was to determine the LRC rate at 1 year in the experimental arm (group B). We considered that a number of 40 patients would be enough to allow for an estimation of LRC with sufficient accuracy. Due to the special characteristics of patients with head and neck cancer, we included 10% additional patients in each arm to account for potential patient drop-outs. This resulted in a total of 90 patients, 45 in each arm.
An intent-to-treat analysis was performed. Descriptive statistics including mean, standard deviation, median, minimum and maximum for continuous data and number and percentage of subjects for categorical data were used to describe patient demographic-, pathological-and clinical characteristics. The distributions of LRC, SDFS, EFS and OS were estimated using the actuarial method (LRC) or the Kaplan-Meier method. Despite being a non-comparative trial, the log-rank test was performed to test differences in survival between both treatment groups. The actuarial method was used to display LRC over time. Differences in the LRC rate at 1 year between treatment groups were assessed using a χ 2 test. All the efficacy parameters were calculated from the initial date of the assigned treatment (first dose of cetuximab).
results patient characteristics
Ninety-one patients were enrolled, 45 in the arm A and 46 in the arm B. Demographic, clinical and pathological characteristics were similar between the two treatment groups ( Table 1) . The most frequent primary tumor site was the tonsil, although in some cases the tumor volume affected more than one site. The analysis of HPV status was decided retrospectively and that was because we could only analyze 42 patients' samples (46% of the total). Biomarker status was evaluated in 29 patients in each group but the results did not identify any subgroup with enough power to detect differences (supplementary Table S1 , available at Annals of Oncology online). The median follow-up time was 44.6 months (range 34-56.6 months).
treatment exposure and compliance
During concomitant treatment, none of the patients discontinued treatment in group B. However, there were two treatment discontinuations in group A (one adverse event and one loss of follow-up). Treatment compliance during the concomitant phase was high and similar in both groups. More than 85% of the patients received the planned dose of RT and cetuximab, whereas four patients (9%) in group A and six 
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Annals of Oncology (13%) in group B received less than the planned 69.9 Gy. RT delays of >10 days occurred in only two patients (one due to radiation dermatitis and one due to a tumor bleeding). The median number of doses of xetuximab during concomitant treatment was seven in both groups. In group B, compliance during the adjuvant phase was also high. Four patients (9%) did not start adjuvant cetuximab because of consent withdrawals after RT (N = 2) and adverse events (N = 2, one intestinal occlusion and one mucositis grade 4 complicated with pneumonia and death). Thirty-seven patients (79%) completed >10 weeks of adjuvant treatment.
efficacy
The response rate at the first evaluation (12 weeks after the end of RT) was higher in the adjuvant group (group B): overall response was 85% in the group A [complete response (CR) rate of 56% and partial response (PR) rate of 29%] and 96% in the group B (CR rate of 65% and PR rate of 30%; P-value = 0.073).
Patients not evaluated at this point were due to consent withdrawal (two in the group A) or death: three patients in the group A and two in the group B died within 12 weeks after the last RT treatment. A salvage cervical neck dissection was indicated in six patients (13%) in the group A and in four (8%) in the group B. This resulted in an initial LRC of 73% for group A and 83% for group B (LRC at this point includes initial CR, PR that finally were confirmed as CR, and partial cervical responses salvaged with the neck dissection). This initial difference was maintained at 1 year (the primary end point of the study), with 1-year LRC of 59% for group B versus 47% for group A (P-value = 0.25). This initial advantage observed in the group B was lost after 2 years of follow-up, with similar LRC rates at 2 and 3 years in both treatment groups. (Table 2 and Figure 1 ).
Between the first and the second year following adjuvant treatment, five patients in group B and only one in group A had a locoregional recurrence. With respect to the secondary end point, the results obtained were as follows: median SDFS and EFS in the group A: 35.3 months (9.1-not reached) and 18.4 months (6.7-51.2), respectively versus 41 months (9.8-50.8) and 23.7 months (9.3-50.8) for the group B (P-value = 0.94 and 0.48), respectively. There were only slightly differences in the curves of OS between groups till the third year, with a median OS rate 33.6 months (10.8-51.2) for group A and 39.9 months (19.6-not reached) for group B (P-value = 0.44; Figure 2 ). Numbers of deaths at the data cut-off were nearly the same in both groups, with similar results with respect to the causes of deaths (supplementary Table S1 , available at Annals of Oncology online).
In all, eight secondary tumors were diagnosed during the follow-up period: two in group A (lung cancer; N = 1 and head and neck cancer, N = 1) and six in group B (lung cancer; N = 3, pancreas; N = 1 and prostate; N = 2).
toxic effect
Adverse events during concomitant treatment were comparable between both treatment groups. Only one patient discontinued cetuximab because of a hypersensitivity reaction after the first infusion (group A). Cetuximab was generally well tolerated; most adverse events were grade 1-2 and mainly included skin rash, mucositis, odynophagia and asthenia. There were few episodes of grade 4 toxic effect: 4 mucositis [1 in the arm A (2%) and 3 in the arm B (7%)], 1 skin toxic effect (arm A) and Annals of Oncology original articles 1 radiation dermatitis (arm A). Only two of them occurred before RT completion (1 mucositis in the arm B and the radiation dermatitis episode). It is noticeable that patients treated with adjuvant cetuximab do recover very soon from toxic effect after combined treatment. Toxic effect due to RT had a similar recovery pattern after completion of RT, with <3% of grade 3-4 adverse events after week 4. Only mild mucositis (grade 1-2) recovered slower in group B. The skin toxic effect was increased during the adjuvancy in the group B, but was mild in the majority of the cases with a clear tendency to improvement with time. Pneumonia was the main cause of infection in these patients with three events (7%) during the adjuvancy in the group B. Hypomagnesemia was not a problem in this trial probably because all the patients received magnesium supplementation at the first detection of magnesium depletion in the blood test. Table 3 shows the main toxic effect in both treatment groups, after administration of RT and until 12 weeks of adjuvant treatment.
discussion
To our knowledge, results of adjuvant treatment approaches to the Bonner schedule have not yet been reported with cetuximab. Our study was designed after the results of the Bonner et al. trial [6] and is part of an attempt to improve those results. We focused only on patients with oropharyngeal cancer to obtain outcomes that would be as homogeneous as possible, and also because the efficacy analysis by tumor location in the Bonner study pointed to the possibility that it is precisely the oropharyngeal cancer which benefited the most from concomitant therapy. Only Argiris et al. [15] added 6 months of maintenance treatment with cetuximab in a schedule that also included induction and concomitant treatment in locally advanced disease. No conclusion related to maintenance treatment was obtained in that trial.
The use of adjuvant cetuximab was supported by our previous preclinical study [7] . We identified an aggressive phenotype in the microscopic residual disease after treatment with RT of a human epidermoid cell line A431. These surviving cells where then injected s.c. into nude mice. The animals receiving adjuvant cetuximab showed a notable negative impact on tumor growth and also on reduction of the aggressiveness of the tumors with lower Ki-67 index and lower tumor-associated angiogenesis. Another important factor for electing cetuximab monotherapy as adjunctive treatment was the potential lower toxic effect (mainly skin toxic effect) in association with RT [6] or chemotherapy in recurrent/ metastatic disease [16] .
In this study, the 12-week adjuvant treatment with cetuximab is a feasible treatment (over 75% of patients received 10 or more doses of adjuvant cetuximab). As expected, the main toxic effect during the adjuvancy was on the skin. No typical toxic effect associated with the concomitant phase of cetuximab plus RT was worsened or lengthened during the adjuvant treatment. This would favor the use of cetuximab in combination with other drugs in future adjuvant trials. The only adverse event clearly increased during the maintenance phase with cetuximab was the occurrence of pneumonia (none versus 7%). This is in accordance correlate with the finding of an increase in the sepsis rate (5%) in patients treated with chemotherapy and cetuximab in the EXTREME study [16] . A possible explanation for this is an alteration of the immune response in these patients who have also been treated with RT at the beginning of the respiratory tract and who are thus more likely to suffer from microaspiration episodes.
In our study, 12 weeks of maintenance with cetuximab not seem to be enough to remove the microscopically more aggressive residual disease, resulting from previous definitive RT. Although initial efficacy parameters improved in group B, these improvements were not maintained after the first year of follow-up, with a rise of locoregional relapses in this group. original articles
Annals of Oncology
Despite this is not an adequately powered study to answer definitively this question, it seems that the EGFR blockade produced by the maintenance cetuximab may reduce the aggressiveness of the minimal residual disease but is not enough to eliminate it, and it will finally reappear. To help definitively eliminate this residual disease, we should consider the use of cytotoxic drugs having synergistic effects with the EGFR blockade signal due to cetuximab. Taxans have been shown to be active in induction chemotherapy [17] [18] [19] , as well as in recurrent/metastatic disease [20] . In recurrent disease, weekly administration of paclitaxel (Taxol, Bristol-Myers Squibb) is active and well tolerated in the second-line treatment [21] . Further, the combination of cetuximab and weekly paclitaxel in the first-line treatment is feasible and highly active [22] . This last combination might be of special interest in adjuvant treatment, looking for the additive effect of taxanes and cetuximab to overcome the aggressiveness of the residual disease and with acceptable tolerability after curative intent treatment with RT.
In summary, 12 weeks of adjuvant treatment with cetuximab after a definitive treatment with RT plus cetuximab is safe and feasible and seems to improve the LRC at the end of treatment and 1 year later. However, the EGFR blockade alone may not be able to eliminate the minimal residual disease after the definitive treatment; and therefore, this improvement is not maintained throughout the following 1-2 years. This is in accordance with the increase in locoregional recurrences in the second year of follow-up. Additional efforts are warranted to further improve treatment after bioradiation perhaps by differentiating populations according to tumor locations and HPV status.
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